Q1 EPS Forecast for Orchestra BioMed Increased by Analyst

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Investment analysts at HC Wainwright lifted their Q1 2026 EPS estimates for Orchestra BioMed in a research report issued to clients and investors on Monday, March 16th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.33) for the quarter, up from their prior forecast of ($0.42). The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Orchestra BioMed’s Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.53) EPS.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.64. Orchestra BioMed had a negative net margin of 157.40% and a negative return on equity of 184.17%. The business had revenue of $30.92 million during the quarter, compared to analysts’ expectations of $0.93 million.

Other equities research analysts have also issued reports about the stock. TD Cowen initiated coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a “buy” rating for the company. Chardan Capital restated a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a report on Thursday, March 12th. Barclays lifted their price target on Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. Finally, Wall Street Zen upgraded Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Orchestra BioMed presently has a consensus rating of “Moderate Buy” and an average target price of $13.80.

Orchestra BioMed Trading Up 1.3%

Shares of OBIO stock opened at $4.61 on Wednesday. The business has a 50-day moving average price of $4.20 and a two-hundred day moving average price of $3.88. The firm has a market cap of $269.78 million, a P/E ratio of -4.08 and a beta of 0.56. Orchestra BioMed has a 12-month low of $2.20 and a 12-month high of $5.42. The company has a quick ratio of 6.43, a current ratio of 6.45 and a debt-to-equity ratio of 0.27.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new stake in Orchestra BioMed in the 4th quarter worth approximately $38,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Orchestra BioMed during the second quarter valued at approximately $31,000. Virtu Financial LLC purchased a new position in shares of Orchestra BioMed during the fourth quarter valued at approximately $57,000. Creative Planning bought a new position in shares of Orchestra BioMed during the second quarter valued at approximately $40,000. Finally, XTX Topco Ltd purchased a new stake in Orchestra BioMed in the second quarter worth $45,000. Hedge funds and other institutional investors own 53.20% of the company’s stock.

Insider Activity at Orchestra BioMed

In other news, insider David P. Hochman bought 10,000 shares of the company’s stock in a transaction dated Friday, March 13th. The stock was bought at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the acquisition, the insider owned 1,086,467 shares in the company, valued at approximately $4,660,943.43. This trade represents a 0.93% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 8.10% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.